[CHMA] Chiasma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.15 Change: 0.1 (4.88%)
Ext. hours: Change: 0 (0%)

chart CHMA

Refresh chart

Strongest Trends Summary For CHMA

CHMA is in the medium-term up 138% above S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.63 M Cash From Investing Activities10 K Cash From Operating Activities-4.92 M Gross Profit
Net Profit-4.24 M Operating Profit-4.15 M Total Assets72.64 M Total Current Assets71.32 M
Total Current Liabilities3.78 M Total Debt Total Liabilities8.5 M Total Revenue
Technical Data
High 52 week4.24 Low 52 week1.25 Last close4.01 Last change0.5%
RSI71.88 Average true range0.16 Beta0.82 Volume174.71 K
Simple moving average 20 days9.15% Simple moving average 50 days16.6% Simple moving average 200 days46.43%
Performance Data
Performance Week3.62% Performance Month8.67% Performance Quart7.8% Performance Half70.64%
Performance Year150.63% Performance Year-to-date28.94% Volatility daily2.67% Volatility weekly5.98%
Volatility monthly12.25% Volatility yearly42.42% Relative Volume300.96% Average Volume60.04 K
New High New Low

News

2019-03-08 16:05:00 | Chiasma Reports Fourth Quarter and Year End 2018 Results

2019-03-04 16:05:00 | Chiasma to Participate in Three Investor Conferences in March

2019-02-28 08:00:00 | Chiasma Announces Support for Rare Disease Day 2019

2019-02-27 12:56:56 | Have Insiders Been Buying Chiasma, Inc. NASDAQ:CHMA Shares?

2019-01-03 16:05:00 | Chiasma Previews Important Upcoming Milestones

2018-12-21 09:47:02 | Do Directors Own Chiasma, Inc. NASDAQ:CHMA Shares?

2018-11-21 08:55:00 | Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-08 18:03:30 | Chiasma: 3Q Earnings Snapshot

2018-11-08 16:05:00 | Chiasma Reports Third Quarter 2018 Results

2018-11-01 08:00:00 | Chiasma Supports Acromegaly Awareness Day

2018-10-17 16:05:00 | Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association

2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

2018-10-01 16:01:00 | Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

2018-09-20 13:57:56 | One Thing To Consider Before Buying Chiasma Inc NASDAQ:CHMA

2018-09-13 16:01:00 | Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies

2018-08-09 17:47:39 | Chiasma: 2Q Earnings Snapshot

2018-08-09 16:05:00 | Chiasma Reports Second Quarter 2018 Results

2018-07-25 16:05:00 | Chiasma Completes Enrollment of MPOWEREDTM Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

2018-06-18 16:05:00 | Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference

2018-06-14 16:05:00 | Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly

2018-05-14 16:05:00 | Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial

2018-05-10 19:00:48 | Chiasma: 1Q Earnings Snapshot

2018-05-10 16:05:00 | Chiasma Reports First Quarter 2018 Results

2018-03-20 16:23:33 | Chiasma reports 4Q loss

2018-03-20 16:05:00 | Chiasma Reports Fourth Quarter and Year End 2017 Results

2018-03-20 07:40:00 | Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018

2018-03-16 08:00:00 | Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly

2018-03-14 09:42:23 | Want To Invest In Chiasma Inc NASDAQ:CHMA? Here’s How It Performed Lately

2018-03-05 08:00:00 | Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference

2018-02-28 08:45:00 | Chiasma Honors Patients, Researchers for Rare Disease Day 2018

2018-01-08 09:00:00 | Chiasma Reports on Significant Progress Made During 2017

2017-11-09 17:03:37 | Chiasma reports 3Q loss

2017-11-09 16:05:00 | Chiasma Reports Third Quarter 2017 Results

2017-11-07 09:23:35 | Is Chiasma Inc’s CHMA CEO Pay Fair?

2017-11-01 08:50:00 | Chiasma Recognizes Acromegaly Awareness Day

2017-09-27 16:05:00 | Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly

2017-08-10 21:34:52 | Chiasma reports 2Q loss

2017-08-10 16:02:05 | Chiasma Reports Second Quarter 2017 Results

2017-08-10 16:01:08 | Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly

2017-06-19 08:18:43 | Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors

2017-05-05 08:08:29 | Chiasma reports 1Q loss

2017-05-05 08:01:28 | Chiasma Reports First Quarter 2017 Results

2017-03-30 16:05:00 | Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire

2017-03-16 17:06:38 | Chiasma reports 4Q loss

2017-03-16 16:22:39 | CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2017-03-16 16:05:00 | Chiasma Reports Fourth Quarter and Year End 2016 Results

2017-03-01 08:00:00 | Chiasma to Present at the Cowen and Company 37th Annual Health Care Conference

2017-01-17 11:58:09 | Chiasma downgraded by Barclays

2017-01-09 08:17:12 | CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an

2017-01-09 08:00:00 | Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017